Eucontra
68mg Resorbable Implant
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Subdermal
-
Intended Duration:
- Long-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Hera Health Solutions
Details
- API: Etonogestrel
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Cervical Mucus Changes
- Endometrial Changes
- Regimen: 1 Insertion/3 Years
- MPT: Not Potential MPT
- Promising Attributes: BDIs provide a long duration of contraceptive efficacy, removability for the majority of the period of use, and no need to return to a medical provider for removal
Product Status
Active Product Website & Recent Development Announcements
History
2019: Hera Health Solutions announces development of a bioerodible implant & successful seed funding campaign
2022: Developers confirm potential use as a contraceptive
2023: Hera Health Solutions receives National Science Foundation grant to finalize the Eucontra prototype and test the prototype in a clinically relevant animal model, to begin the preparation process for an IND.